.

Make Better Decisions

  • Analyze global market entry opportunities
  • Identify first generic entrants
  • Drug patents in 130+ countries

► See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving 500+ biopharmaceutical companies globally:

Fuji
Fish and Richardson
Queensland Health
Julphar
Colorcon
Covington
McKinsey
Healthtrust
Baxter
Accenture

Generated: September 23, 2017

DrugPatentWatch Database Preview

INNOPRAN XL Drug Profile

« Back to Dashboard

What is the patent landscape for Innopran Xl, and what generic Innopran Xl alternatives are available?

Innopran Xl is a drug marketed by Ani Pharms Inc and is included in one NDA. There is one patent protecting this drug.

This drug has fourteen patent family members in eleven countries.

The generic ingredient in INNOPRAN XL is propranolol hydrochloride. There are twenty-one drug master file entries for this compound. Fifty-six suppliers are listed for this compound. Additional details are available on the propranolol hydrochloride profile page.

Summary for Tradename: INNOPRAN XL

Patents:1
Applicants:1
NDAs:1
Suppliers / Packagers: see list2
Bulk Api Vendors: see list72
Clinical Trials: see list5
Patent Applications: see list2,801
Formulation / Manufacturing:see details
Drug Prices:see details
DailyMed Link:INNOPRAN XL at DailyMed

Pharmacology for Tradename: INNOPRAN XL

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Ani Pharms Inc
INNOPRAN XL
propranolol hydrochloride
CAPSULE, EXTENDED RELEASE;ORAL021438-001Mar 12, 2003BXRXNoNo► Subscribe► SubscribeY ► Subscribe
Ani Pharms Inc
INNOPRAN XL
propranolol hydrochloride
CAPSULE, EXTENDED RELEASE;ORAL021438-002Mar 12, 2003BXRXNoNo► Subscribe► SubscribeY ► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Non-Orange Book Patents for Tradename: INNOPRAN XL

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
9,040,086Timed, sustained release systems for propranolol► Subscribe
9,358,214Timed, sustained release systems for propranolol► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Tradename: INNOPRAN XL

Country Document Number Estimated Expiration
Australia2002330211► Subscribe
Germany60233668► Subscribe
European Patent Office1432411► Subscribe
Norway20041740► Subscribe
Spain2333306► Subscribe
South Korea101090719► Subscribe
Austria442134► Subscribe
Japan4369752► Subscribe
Norway335070► Subscribe
South Korea20040084890► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving 500+ biopharmaceutical companies globally:

Daiichi Sankyo
Cantor Fitzgerald
Baxter
Fish and Richardson
McKesson
AstraZeneca
Healthtrust
Novartis
Medtronic
QuintilesIMS

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted Heap | Mobile and Web Analytics
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot